|
NUFIP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.57589999955677E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.97239999999832E-05 |
| Normal-vs-Stage2 |
2.224100E-04 |
| Normal-vs-Stage3 |
8.00010000023832E-07 |
| Normal-vs-Stage4 |
1.55148999999577E-05 |
| Stage1-vs-Stage2 |
4.425200E-01 |
| Stage1-vs-Stage3 |
8.184100E-02 |
| Stage1-vs-Stage4 |
1.328210E-01 |
| Stage2-vs-Stage3 |
6.258600E-01 |
| Stage2-vs-Stage4 |
5.529200E-01 |
| Stage3-vs-Stage4 |
8.696200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.60199999998945E-06 |
| Normal-vs-AfricanAmerican |
6.172200E-02 |
| Normal-vs-Asian |
4.997200E-04 |
| Caucasian-vs-AfricanAmerican |
2.616000E-01 |
| Caucasian-vs-Asian |
9.772800E-01 |
| AfricanAmerican-vs-Asian |
3.227200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.5561999999969E-05 |
| Normal-vs-Female |
2.05689999999148E-06 |
| Male-vs-Female |
7.403400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.552900E-04 |
| Normal-vs-Age(41-60Yrs) |
3.44120000050907E-07 |
| Normal-vs-Age(61-80Yrs) |
6.53339999989733E-07 |
| Normal-vs-Age(81-100Yrs) |
4.508300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.765600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.324100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.422200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.749200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.747600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.839200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.706100E-02 |
| Classical-VS-Follicular |
3.695800E-03 |
| Classical-VS-Other |
1.306560E-01 |
| Classical-VS-Normal |
2.195900E-04 |
| Tall-VS-Follicular |
9.319400E-01 |
| Tall-VS-Other |
5.985800E-01 |
| Tall-VS-Normal |
6.40349999999623E-05 |
| Follicular-VS-Other |
6.001400E-01 |
| Follicular-VS-Normal |
4.79360000027462E-07 |
| Other-VS-Normal |
6.364500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.24899999956563E-07 |
| Normal-vs-N1 |
1.774360E-04 |
| N0-vs-N1 |
8.120000E-01 |
|
|
